氩氦冷冻对小鼠前列腺癌血管生成影响的实验研究
|
摘要
目的
分析探讨冷冻消融治疗对前列腺癌血管生成及细胞增殖的影响,旨在评价冷冻治疗效果并为冷冻消融综合治疗中晚期前列腺癌提供实验依据。
方法
取C57小鼠100只,随机分两组,A、B两组均制成前列腺癌皮下移植瘤模型,A组行氩氦冷冻治疗(实验组A,n=50),荷瘤对照未行氩氦冷冻治疗(对照组B,n=50)。观察小鼠皮下肿瘤生长情况。A、B两组小鼠于冷冻术后1d、3d、5d、7d、14d分别采取肿瘤组织,每个时间点各取10只小鼠,用免疫组化方法测MVD、VEGF及Ki67。
结果
1接种后5天小鼠右侧腹股沟处可以扪及肿瘤长出。接种后2周,局部可形成一直径1.0～1.5cm的肿块,100只C57小鼠全部接种成功。
2冷冻组小鼠在冷冻后MVD、VEGF及Ki67蛋白表达均出现下降,低峰值出现在3d,然后缓慢回升,与对照组相比,有显著性差异(P＜0.01),冷冻组各时间点比较,经统计分析有显著性差异(P＜0.05)。对照组各时间点MVD、VEGF及Ki67蛋白表达无明显变化(P＞0.05)。冷冻后前列腺癌VEGF蛋白表达水平与MVD呈显著正相关(相关系数r=0.8793,P＜0.01)。VEGF蛋白表达水平与ki67呈显著正相关(相关系数r=0.6921,P＜0.01)。Ki67表达水平与MVD呈显著正相关(相关系数r=0.7614,P＜0.01)。
结论
氩氦冷冻消融治疗前列腺癌后,随观察时间延长,局部肿瘤组织内MVD、VEGF、Ki67呈先降低后升高的动态变化过程,且三者呈明显正相关。而冷冻消融联合抗血管生成可能是中晚期前列腺癌综合治疗的有效手段。
Objective
The purpose of this study was to explore the effect of Argon-Helium Cryosurgery(AHCS) on the mice of bearing RM-1 prostate cancer through detecting angiogenesis and cell proliferation in prostate cancer of mice,To analyze the effects of cryotherapy on VEGF、Ki67 protein expression and microvesel density of prostate cancer,and provide an experimental evidence on cryoablation comprehensive treatment for advanced prostate cancer.
Materials and Methods
A hundred mice experimental models with RM-1 prostate cancer were established,experimental mice were randomized into two group:the AHCS therapy group(group A,n=50),the tumor-bearing control group(group B,n=50).after the AHCS therapy,Peripheral tumor tissues of 50 mice were obtained from group A at 1d,3d,5d,7d,14d.at the same time,the tumor-bearing control group B(not do the AHCS therapy),tumor tissues of 50 mice were obtained from group B at 1d,3d,5d, 7d.14d.MVD,VEGF,Ki67 protein expression were detected by immunohistochemical staining at different time after the freezing.
Results
1.Prostate cancer cell has stable biology characteristics,and the incadence of cancer was 100%.
2.MVD、VEGF and Ki67 protein expressions in freezing group were decreased.The lowest value was detected at the third day after freezing.The value increased slowly after that.There was no change in MVD and VEGF,Ki67 protein expressions at different time in control group(P＞0.05),There were significant change in MVD,VEGF,Ki67 protein expressions at different time in freezing group(P＜0.05). Correlation analysis showed suggest a positive correlation between VEGF protein expression and MVD(r=0.8793,P＜0.01) suggest a positive correlation between ki67 protein expression and MVD(r=0.7614,P＜0.01).suggest a positive correlation between VEGF protein expression and ki67(r=0.6921,P＜0.01).
Conclusion
After argon-helium cryoablative treatment for prostate cancer,local tumor MVD, VEGF,Ki67 was reduced at the first day,the lowest value was detected at the third day after freezing,then increase,in the dynamic process of change,MVD,VEGF, Ki67was positively correlated.And cryoablation joint anti-angiogenesis is an effective means that may be integrated in the treatment of advanced prostate cancer.
分析探讨冷冻消融治疗对前列腺癌血管生成及细胞增殖的影响,旨在评价冷冻治疗效果并为冷冻消融综合治疗中晚期前列腺癌提供实验依据。
方法
取C57小鼠100只,随机分两组,A、B两组均制成前列腺癌皮下移植瘤模型,A组行氩氦冷冻治疗(实验组A,n=50),荷瘤对照未行氩氦冷冻治疗(对照组B,n=50)。观察小鼠皮下肿瘤生长情况。A、B两组小鼠于冷冻术后1d、3d、5d、7d、14d分别采取肿瘤组织,每个时间点各取10只小鼠,用免疫组化方法测MVD、VEGF及Ki67。
结果
1接种后5天小鼠右侧腹股沟处可以扪及肿瘤长出。接种后2周,局部可形成一直径1.0～1.5cm的肿块,100只C57小鼠全部接种成功。
2冷冻组小鼠在冷冻后MVD、VEGF及Ki67蛋白表达均出现下降,低峰值出现在3d,然后缓慢回升,与对照组相比,有显著性差异(P＜0.01),冷冻组各时间点比较,经统计分析有显著性差异(P＜0.05)。对照组各时间点MVD、VEGF及Ki67蛋白表达无明显变化(P＞0.05)。冷冻后前列腺癌VEGF蛋白表达水平与MVD呈显著正相关(相关系数r=0.8793,P＜0.01)。VEGF蛋白表达水平与ki67呈显著正相关(相关系数r=0.6921,P＜0.01)。Ki67表达水平与MVD呈显著正相关(相关系数r=0.7614,P＜0.01)。
结论
氩氦冷冻消融治疗前列腺癌后,随观察时间延长,局部肿瘤组织内MVD、VEGF、Ki67呈先降低后升高的动态变化过程,且三者呈明显正相关。而冷冻消融联合抗血管生成可能是中晚期前列腺癌综合治疗的有效手段。
Objective
The purpose of this study was to explore the effect of Argon-Helium Cryosurgery(AHCS) on the mice of bearing RM-1 prostate cancer through detecting angiogenesis and cell proliferation in prostate cancer of mice,To analyze the effects of cryotherapy on VEGF、Ki67 protein expression and microvesel density of prostate cancer,and provide an experimental evidence on cryoablation comprehensive treatment for advanced prostate cancer.
Materials and Methods
A hundred mice experimental models with RM-1 prostate cancer were established,experimental mice were randomized into two group:the AHCS therapy group(group A,n=50),the tumor-bearing control group(group B,n=50).after the AHCS therapy,Peripheral tumor tissues of 50 mice were obtained from group A at 1d,3d,5d,7d,14d.at the same time,the tumor-bearing control group B(not do the AHCS therapy),tumor tissues of 50 mice were obtained from group B at 1d,3d,5d, 7d.14d.MVD,VEGF,Ki67 protein expression were detected by immunohistochemical staining at different time after the freezing.
Results
1.Prostate cancer cell has stable biology characteristics,and the incadence of cancer was 100%.
2.MVD、VEGF and Ki67 protein expressions in freezing group were decreased.The lowest value was detected at the third day after freezing.The value increased slowly after that.There was no change in MVD and VEGF,Ki67 protein expressions at different time in control group(P＞0.05),There were significant change in MVD,VEGF,Ki67 protein expressions at different time in freezing group(P＜0.05). Correlation analysis showed suggest a positive correlation between VEGF protein expression and MVD(r=0.8793,P＜0.01) suggest a positive correlation between ki67 protein expression and MVD(r=0.7614,P＜0.01).suggest a positive correlation between VEGF protein expression and ki67(r=0.6921,P＜0.01).
Conclusion
After argon-helium cryoablative treatment for prostate cancer,local tumor MVD, VEGF,Ki67 was reduced at the first day,the lowest value was detected at the third day after freezing,then increase,in the dynamic process of change,MVD,VEGF, Ki67was positively correlated.And cryoablation joint anti-angiogenesis is an effective means that may be integrated in the treatment of advanced prostate cancer.
引文
[1]American Cancer Society.Cancer Facts&Figures 2006[J].Atlanta:American Cancer Society;2006.
[2]李绍杰,孙忠全.激素难治性前列腺癌治疗进展[J].老年医学与保健,2007,(13)6:389-391.
[3]李金华,陈志强.局限性前列腺癌冷冻疗法的意义[J].中华泌尿外科杂志,2001,22(11):701-706.
[4]邢文阁,郭志,王海涛,等.42例直肠超声引导经皮氩氦冷冻治疗中晚期前列腺癌[J].中华放射学杂志,2008,42(8):807-811.
[5]Ruf G.open perineal cryosurgery in carcinoma of the prostate -a possible curative alternative[J].Urol Res,1988,14:3-7.
[6]宋冬梅,张丽莎,王宝山,等.低氧条件下人参皂甙Rg3诱导人喉鳞癌细胞凋亡及对HIF-1a和VEGF表达的影响[J].肿瘤防治研究,2008,35(8):533-537.
[7]曾益新,吕有勇,朱明华,等.肿瘤学[M].第二版.北京:人民卫生出版社,2003:250-258.
[8]李兴謇,杨志芳,易继林,等.肝癌经肝动脉栓塞化疗后VEGF和CD44v6表达的意义[J].世界华人消化杂志,2006,14(13):1305-1308.
[9]Valerie Forest,Michel Peoch,Lydia Camposa,et al.Benefit of a combined treatment of cryotherapy and chemotherapy on tumour growth and late cryo-induced angiogenesis in a non-small-cell lung cancer model[J].Lung Cancer,2006,54(1):79-86.
[10]牛庆亮,王滨,刘金刚,等.良性前列腺增生、前列腺癌MSCT多期增强扫描与MVD、VEGF表达的相关性研究[J].中国临床医学影像杂志,2008,19(1):18-22.
[11]Delongchamps NB,Peyromaure M.The role of vascular endothelial growth factor in kidney and prostate cancer[J].Can J Urol,2007,14(5):3669-3674.
[12]高吴阳,胡传义.血管内皮生长因子在前列腺癌中的表达及与肿瘤微血管密度和肿瘤细胞增殖的关系[J].陕西医学杂志,2005,34(5):541-567.
[13]Sawhney N,Hall PA.Ki67-structure,function and new antibodies[J].Pathology, 1992,168(2):161-162.
[14]Wei H.Medical Experiment:Animal Medicine[M].Chengdu:Sichuan Science Technology Publishing Company,1998,298-300.
[15]Papamichail M,Perez SA,Gritzapis AD,et al.Natural killer lymphocytes:biology,development,and function[J].Cancer Immunol immunother,2004,53(3):176-186.
[16]Gonder M H.Cryosurgical treatment of the prostate[J].Invest Urol,1966,33(2):372-378.
[17]Gonder MJ Experimental protate cryosurgery[M].Invest Urol,1984,30(1):610-619.
[18]Rouva OP.Cryosurgery of the prostate under local ancsthesia[J].J Urol,1969,102:244-245.
[19]Soanes WA.Use of cryosurgery in prostatic cancer[J].J Urol,1968,99(4):793-797.
[20]Onik G.Trantsrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate Cancer[J].J Urol,1993,72(1):1291-1299.
[21]Gage AA,Bavstg RC,et al.Mechanisons of tissue injury in cryotherpy[J].Cryobiology,1998,37:171-186
[22]Kaygusuz G,Tulunay O,Baltaci S,et al.Microvessel density and regulators of angiogenesis in malignant and nonmalignant prostate tissue[J].Int Urol Nephrol.,2007,39(3):841-50.
[23]Scomro IN,Holmer J,Whimster Wf,et al.Predicting prognosis in lung cancer:use of proliferation marker,Ki67 mono-clonal antibody[J].J Pak Med Assoc,1998,48(3):66-78.
[24]王玲,董昌元,贺伟,等.经直肠彩色多普勒超声对前列腺增生和前列腺癌的血流动力学研究[J].中国超声医学杂志,2001,17(2):144-147.
[25]董昌元,王玲,王贤明,等.前列腺癌组织中PCNA、MVD表达与彩超血流检测的研究[J].中国临床医学影像杂志,2007,18(1):56-58.
[26]Halvorsen O J,Haukaas S,Hoisarter PA,et al.Independent prognostic importance of microvessel density in clinically localized prostate cancer[J].Anticancer Res,2008,20(5):3791-3795.
[27]Horak ER,Leek R,Klenk N,et al.Harris AL.Angiogenesis,assessed by platelet/endothelial cell adhesion molecule antibodies,as indicator of node metastases and survival in breast cancer[J].Lancet,1992,340(1):1120-1124.
[28]Weidner N,Barbarishi M,Gasparini G,et al.Microvascular density qualification in breast carcinoma[J].Appl Immunhistochemistry,1995,9(2):75-79.
[29]Sugawara Y,Makuuchi M,Harihara Y,et al.Tumor angiogenessis in gallbladder carcinoma[J].epatogastroenterology,1999,46(7):1682-1686.
[30]Martin L,Holcombe C,Renshow C,et al.Standandising the counting technique of neovascularisation in invasive breast cancer[J].Breast Cancer Res Treat,1996,37(3):34-39.
[31]Ngio,Poon RT,Lee JM,et al.Microvessel Density,Vacular Endothelial Growth Factor and Its receptors Flt-1 and Flt-1/KDR in Hepatocellar[J],J clin pathol,2001,116(6),838-845.
[32]张凡,常永霞,赵秀兰,等.HIF-la、VEGF、p53、CD31对小鼠黑色素移植瘤血管生成拟态作用的研究[J].中国老年杂志,2008,28(5):1773-1776.
[33]Hanahan D,Folkman J.Patterns and emerging mechanisms of the angiogenicseich during tumorigenesis[J].Cell,1996,86(3):353-364.
[34]Lachgar S,Moukadiri H,Jonca F,et al.Vascular endothelial growth factor is an autocrine growth factor for hair dermal papilla cells[J].J Invest Dermatol,1996,106(1):17-23.
[35]David W.Vascular endothelial growth factor is a secreted angiogenic mitogen[J].Science,1989,24(6):1306-1309.
[36]Leuy AP,Levy NS,Gddberg MA,et al.Posttrandcriptional regulation of Vascular tridothelial growth factor by hypoxia[J].Biol Chem,1996,271(5):2744-2753.
[37]Yang J,Wu HF,Qian LX,et al.Increased expressions of vascular endothelial growth factor(VEGF),VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression Asian[J].J Androl,2006,8(2):169-175.
[38]郑翔,涂汉军,李新建等,冷冻对小鼠G422胶质瘤血管生成及VEGF表达的实验研究[J].郧阳医学院学报,2001,20(2):65-67.
[39]牛庆亮,等.在良性前列腺增生、前列腺癌MSCT多期增强扫描与MVD、VEGF表达的相关性研究[J].中国临床医学影像杂志,2008,19(1):18-22.
[40]Poston RS,Ennen M,Pollard J,et al.Ex Vivo GeneTherapy Prevents Chronic Graft Vascular Disease in Cardiac Allograft[J].J Thorac Cardiovasc Surg,1996,116(3):386-396.
[41]Leuy A P,Levy N S,Gddberg M A,et al.Posttrandcriptional regulation of Vascular tridothelial growth factor by hypoxia[J].Biol Chem,1996,271(5):2744-2753.
[42]Konishi T,Huang CL,Adachi M,et al.The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers[J].Int J Oncol,2000,16(3):501.
[43]Hou Q,Cymbalyuk E,Hsu SC,et al.Apoptosis modulatory activities of transiently expressed Bcl-2:roles in cytochrome C release and Bax regulation[J].Apoptosis,2003,8(6):617-627.
[44]Zhong H,De Marzo AM.Laughner E.el al.OverexDression of hypoxia inducible factor-1 alpha in common human cancers and their metastases[J].Cancer Research,1999,59(1):5830-5835.
[45]Bryant RJ,Banks PM,Malley DP,et al.Ki67 staining pattern as a diagnostic tool in the evaluation of lympho proliferative disordres[J].Histopathology,2006,48(5):505-515.
[46]Pisani T,Pantellini F,Centanni M,et al.Immunocytochemical expression of Ki67and laminin in Hurthle cell adcnomas and carcinomas[J].Anticancer Res,2003,23(4):3323-3326.
[47]林海利,郑周达,陈森期,等.ki67、p504s、p53联合检测在前列腺癌中的临床意义研究[J].中华泌尿杂志,2008,23(5):123-126.
[48]方志启,吴刚,陈晓宇等增殖和凋亡基因Ki—67、bcl—2、bax在前列腺增生、前列腺癌组织细胞中的表达及相关性[J].安徽医科大学学报,2007,42(4):391-394.
[49]阎洪涛,龚百生,廖勇,等.前列腺癌P53和PCNA表达的相关性研究[J].四川医学,2005,26(4):429-431.
[1]Folkman J.Tumor angiogenesis:rapeutic implications [J].N En-J,1971,285(20):1182-1186.
[2]Folkman J.Anti—angiogenesis:new concept for therapy of solid tumor3 [J].Anm Surg,1972,175(3):409-416.
[3]Kuiper RA,Schellens JH,Blijham GH,et al.Clinical research on antiangiogenic therapy [J].Pharmacol Res,1998,37(1):12-17.
[4]Maeda K,Chung YS,Takatsuka S,et al.Tumor angiogenesis as a predictor of recurrence in gastric carcinoma [J].J Clin Oncol,1995,13(2):477-481.
[5]Folkman J,Shing Y.Angiogenesis [M].J Bio Chem,1992,26(7):10931-37.
[6]Ohea H,Takagi H,Suzuma K,et al.Hypoxia and vascular endothelial growth factor selective up regulate angiopoietin-2 in bovine microvascular endothelial cells [J].J Biol hem,1999,274(2):15732-15746.
[7]Gunga HC,Kirsch K,Rocker L,et al.Vascular endothelial growth factor in exercising humans under different environmental conditions[J].Eur J Appl Physiol,1999,79(5):484-489.
[8]Norio H,Hisashi T,Mitsuo T,et al.Hepatocyte growth factorpromotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine [J].Oncogene,2002,21(7):1791-1977.
[9]Weidner N,Semple JP,Welch JR,et al.Tumor angiogenesis and metastasis-correlation in invasive breast cancer [J].N Engl JMed,1991,324 (5):111-114.
[10]Lewis JS,Landers RJ,Underwood JC,et al.Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas [J].J Pathol,2000,192(3):150-153.
[11]Wirigmann Vs,Plate KH,et al.genetics and cell biology of hemangioblastomis [J].Histol Histopathol,1996,11(4):1049-1061.
[12]Vahola RP,Salven P,Heikkila J,et al.VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer [J].Am.Patho,1999,154 (1):1381-1390.
[13]Witmer,AN,van Blijswijk BC,Hoffman,TA.et,al.VEGFR-3 in adult angiogenesis [J].Schlingemann Pathol,2001,195(7):490-497.
[14]Aguayo A,O'Brien S,Keating M,et al.Clinical relevance of intreelluar vascular endothelial growth factor levels in B-cell chronic lymphocyte leukemia [J].Blood,2000,96(2):769-770.
[15]Karkkainen MJ,Makinen T,Alitalo K.Lymphaticendothelium:a new frontier of metastasis research [J].Nat Cell Biol,2002,4(1):E2-5.
[16]Gasparini G,Toi M,Gion M,et al.Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma [J].J Natl Cancerlnst,1997,89(2):139-141.
[17]Frelin C,Ladoux A,Dangelo G.Vascular endothelial growth factors and angiogenis [J].Ann Endcefinol Paris,2000,61(1):70-74.
[18]Skobe M,Hawighorst T,Jackson DG,et al.Induction of tumorlym phanglogenesis by VEGF-C promotes breast cancer metastasis [J].Nat Med,2001,7(2):192-198.
[19]Joukov V,Pajusola K,Kaipainen A,et al.A novel vascular endothelial growth factor.VEGF-C is a ligand for the FLT4 (VEGFR-3) and KDR (VEGFR-2)receptor tyrosine kinases[J].EMBO J,1996,15(2):290-297.
[20]Jacquemier J,Mathoulin-Portier MP,Vahola R,et al.Prognosis of breast carcinoma lymphangiogenesis evaluated by immunohistochemicnal investigation of vascular endothelial growth factor receptor 3[J].Int J Cancer,2000,89(1): 69-73.
[21]Veikkola T,Jussila L,Makinen T,et aL.Signaling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice [J].EMBO J,2001,20(6):1223-1229.
[22]Jershenwald JE,Fidler U.et al.Targeting lymphatic metastasis [J].Science,2002,29(54):1811-1819.
[23]Mattila MT,Ruohola JK,Karpanen T,et al.VEGF C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors [J].Int J Caneer,2002,98:946-951.
[24]Jacquemier MJ,Mathoulin-Portier R,Vahola,E.et al.Prognosis of breast carcinoma lymphanogenesis evaluated by immunohistochemical investigation of vascular-endothelial-growth-factorreceptor [J].Bimbaum,2000,Int.Cancer89 (5):69-73.
[25]Salven P,Lymlbossaki A,Heikkila P,et al.Vascular endothelial growth factor VEGF-B and VEGF-C are expressed in human tumor [J].Am J pathol,1998,153(1):103-108.
[26]Vander Geer P,Hunter T,Lindberg RA.et al.Receptor protein-Tyrosine kinases and their signal transduction pathways [J].Annu Rev Cell Biol,1994,4(1):10251-10257.
[27]Mattern J,Koomagi R,Volm M.et al.Vascular endothelial growth factor expression and angiogenesis in no small cell lung carcinomas [J].International Journal of Oncology,1995,6(1):1059-1062.
[28]Delongchamps NB,Peyromaure M,et al.The role of vascular endothelial growth factor in kidney and prostate cancer [J].Can J Urol,2007,14(5):3669-3677.
[29]Liu F.Zhang YJ.et al.Roles of VEGF-C and its receptor Fit-4 in proliferation and metastasis of primary breast cancer[J].Ai Zheng.2003,22(10):1053-1056.
[30]Yang J,Wu HF,Qian LX,et al.Increased expressions of vascular endothelial growth factor (VEGF),VEGF-C and VEGF receptor-3 in prostate cancer tissue areassociated with tumor progression [J].Asian J Androl,2006,8(2):169-75.
[31]Kral J,Waltenberger J,et al.The vascular endothelia]growth factor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells[J].J Biol Chem,1997,272(51):32521-32527
[32]Dvorak H F,Broun LF,Detmar M,et al.vascular permeability factor/vascular endothelial growth factor,micro vascular hyper-permeability and angiogenesis[J].Am I pathol,1995,14(6):1029-1034
[33]Koseoglu RD,Erdemir F,Parlaktas BS,et al.Effect of chronic prostatitis on angiogenic activity and serum prostate specific antigen level in benign prostatic hyperplasia [J].Kaohsiung J Med Sci,2007,23(8):387-394.
[34]Sunny Y.Wong,Herbert Haack,et al.Tumor-Secreted Vascular Endothelial Growth Factor-C Is Necessary for Prostate Cancer Lymphangiogenesis,but Lymphangiogenesis Is Unnecessary for Lymph Node Metastasis [J].Cell and Tumor Biology,2007,65(2):110-116.
[35]Yi T,Yi Z,Cho SG,Luo J,et al.Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling[J].Cancer Res,2008,Mar 15,68(6):1843-1850.
[36]Peyromaure M,Badoual C,Camparo P,et al.Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer [J].Oncol Res.,2007,18(1):145-149.
[37]Peyromaure M,Camparo P,Badoual C,et al.The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostate-ctomy [J].BJU Int.,2007,99(5):1150-1153.
[38]Mao K,Camparo P,Badoual C,et al.The association of vascular endothelial growth factor receptor-1 with the risk of cancer progression following radical prostatectomy [J].Oncol Rep,2008,19(1):171-175.
[39]West AF,O'Donnell M,Charlton RG,et al.Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinic pathologic parameters in human prostate cancer [J].2001,85(4):576-583.
[40]Huber PE,Bischof M,Jenne J,et al.Trimodal cancer treatment:beneficial effects of combined anti angiogenesis,radiation,and chemotherapy [J].Cancer Res,2005,65(9):3643-3655.
[41]Jennbacken K,Vallbo C,Wang W,et al.Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis [J].Prostate,2005,65(2):110-116.
[2]李绍杰,孙忠全.激素难治性前列腺癌治疗进展[J].老年医学与保健,2007,(13)6:389-391.
[3]李金华,陈志强.局限性前列腺癌冷冻疗法的意义[J].中华泌尿外科杂志,2001,22(11):701-706.
[4]邢文阁,郭志,王海涛,等.42例直肠超声引导经皮氩氦冷冻治疗中晚期前列腺癌[J].中华放射学杂志,2008,42(8):807-811.
[5]Ruf G.open perineal cryosurgery in carcinoma of the prostate -a possible curative alternative[J].Urol Res,1988,14:3-7.
[6]宋冬梅,张丽莎,王宝山,等.低氧条件下人参皂甙Rg3诱导人喉鳞癌细胞凋亡及对HIF-1a和VEGF表达的影响[J].肿瘤防治研究,2008,35(8):533-537.
[7]曾益新,吕有勇,朱明华,等.肿瘤学[M].第二版.北京:人民卫生出版社,2003:250-258.
[8]李兴謇,杨志芳,易继林,等.肝癌经肝动脉栓塞化疗后VEGF和CD44v6表达的意义[J].世界华人消化杂志,2006,14(13):1305-1308.
[9]Valerie Forest,Michel Peoch,Lydia Camposa,et al.Benefit of a combined treatment of cryotherapy and chemotherapy on tumour growth and late cryo-induced angiogenesis in a non-small-cell lung cancer model[J].Lung Cancer,2006,54(1):79-86.
[10]牛庆亮,王滨,刘金刚,等.良性前列腺增生、前列腺癌MSCT多期增强扫描与MVD、VEGF表达的相关性研究[J].中国临床医学影像杂志,2008,19(1):18-22.
[11]Delongchamps NB,Peyromaure M.The role of vascular endothelial growth factor in kidney and prostate cancer[J].Can J Urol,2007,14(5):3669-3674.
[12]高吴阳,胡传义.血管内皮生长因子在前列腺癌中的表达及与肿瘤微血管密度和肿瘤细胞增殖的关系[J].陕西医学杂志,2005,34(5):541-567.
[13]Sawhney N,Hall PA.Ki67-structure,function and new antibodies[J].Pathology, 1992,168(2):161-162.
[14]Wei H.Medical Experiment:Animal Medicine[M].Chengdu:Sichuan Science Technology Publishing Company,1998,298-300.
[15]Papamichail M,Perez SA,Gritzapis AD,et al.Natural killer lymphocytes:biology,development,and function[J].Cancer Immunol immunother,2004,53(3):176-186.
[16]Gonder M H.Cryosurgical treatment of the prostate[J].Invest Urol,1966,33(2):372-378.
[17]Gonder MJ Experimental protate cryosurgery[M].Invest Urol,1984,30(1):610-619.
[18]Rouva OP.Cryosurgery of the prostate under local ancsthesia[J].J Urol,1969,102:244-245.
[19]Soanes WA.Use of cryosurgery in prostatic cancer[J].J Urol,1968,99(4):793-797.
[20]Onik G.Trantsrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate Cancer[J].J Urol,1993,72(1):1291-1299.
[21]Gage AA,Bavstg RC,et al.Mechanisons of tissue injury in cryotherpy[J].Cryobiology,1998,37:171-186
[22]Kaygusuz G,Tulunay O,Baltaci S,et al.Microvessel density and regulators of angiogenesis in malignant and nonmalignant prostate tissue[J].Int Urol Nephrol.,2007,39(3):841-50.
[23]Scomro IN,Holmer J,Whimster Wf,et al.Predicting prognosis in lung cancer:use of proliferation marker,Ki67 mono-clonal antibody[J].J Pak Med Assoc,1998,48(3):66-78.
[24]王玲,董昌元,贺伟,等.经直肠彩色多普勒超声对前列腺增生和前列腺癌的血流动力学研究[J].中国超声医学杂志,2001,17(2):144-147.
[25]董昌元,王玲,王贤明,等.前列腺癌组织中PCNA、MVD表达与彩超血流检测的研究[J].中国临床医学影像杂志,2007,18(1):56-58.
[26]Halvorsen O J,Haukaas S,Hoisarter PA,et al.Independent prognostic importance of microvessel density in clinically localized prostate cancer[J].Anticancer Res,2008,20(5):3791-3795.
[27]Horak ER,Leek R,Klenk N,et al.Harris AL.Angiogenesis,assessed by platelet/endothelial cell adhesion molecule antibodies,as indicator of node metastases and survival in breast cancer[J].Lancet,1992,340(1):1120-1124.
[28]Weidner N,Barbarishi M,Gasparini G,et al.Microvascular density qualification in breast carcinoma[J].Appl Immunhistochemistry,1995,9(2):75-79.
[29]Sugawara Y,Makuuchi M,Harihara Y,et al.Tumor angiogenessis in gallbladder carcinoma[J].epatogastroenterology,1999,46(7):1682-1686.
[30]Martin L,Holcombe C,Renshow C,et al.Standandising the counting technique of neovascularisation in invasive breast cancer[J].Breast Cancer Res Treat,1996,37(3):34-39.
[31]Ngio,Poon RT,Lee JM,et al.Microvessel Density,Vacular Endothelial Growth Factor and Its receptors Flt-1 and Flt-1/KDR in Hepatocellar[J],J clin pathol,2001,116(6),838-845.
[32]张凡,常永霞,赵秀兰,等.HIF-la、VEGF、p53、CD31对小鼠黑色素移植瘤血管生成拟态作用的研究[J].中国老年杂志,2008,28(5):1773-1776.
[33]Hanahan D,Folkman J.Patterns and emerging mechanisms of the angiogenicseich during tumorigenesis[J].Cell,1996,86(3):353-364.
[34]Lachgar S,Moukadiri H,Jonca F,et al.Vascular endothelial growth factor is an autocrine growth factor for hair dermal papilla cells[J].J Invest Dermatol,1996,106(1):17-23.
[35]David W.Vascular endothelial growth factor is a secreted angiogenic mitogen[J].Science,1989,24(6):1306-1309.
[36]Leuy AP,Levy NS,Gddberg MA,et al.Posttrandcriptional regulation of Vascular tridothelial growth factor by hypoxia[J].Biol Chem,1996,271(5):2744-2753.
[37]Yang J,Wu HF,Qian LX,et al.Increased expressions of vascular endothelial growth factor(VEGF),VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression Asian[J].J Androl,2006,8(2):169-175.
[38]郑翔,涂汉军,李新建等,冷冻对小鼠G422胶质瘤血管生成及VEGF表达的实验研究[J].郧阳医学院学报,2001,20(2):65-67.
[39]牛庆亮,等.在良性前列腺增生、前列腺癌MSCT多期增强扫描与MVD、VEGF表达的相关性研究[J].中国临床医学影像杂志,2008,19(1):18-22.
[40]Poston RS,Ennen M,Pollard J,et al.Ex Vivo GeneTherapy Prevents Chronic Graft Vascular Disease in Cardiac Allograft[J].J Thorac Cardiovasc Surg,1996,116(3):386-396.
[41]Leuy A P,Levy N S,Gddberg M A,et al.Posttrandcriptional regulation of Vascular tridothelial growth factor by hypoxia[J].Biol Chem,1996,271(5):2744-2753.
[42]Konishi T,Huang CL,Adachi M,et al.The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers[J].Int J Oncol,2000,16(3):501.
[43]Hou Q,Cymbalyuk E,Hsu SC,et al.Apoptosis modulatory activities of transiently expressed Bcl-2:roles in cytochrome C release and Bax regulation[J].Apoptosis,2003,8(6):617-627.
[44]Zhong H,De Marzo AM.Laughner E.el al.OverexDression of hypoxia inducible factor-1 alpha in common human cancers and their metastases[J].Cancer Research,1999,59(1):5830-5835.
[45]Bryant RJ,Banks PM,Malley DP,et al.Ki67 staining pattern as a diagnostic tool in the evaluation of lympho proliferative disordres[J].Histopathology,2006,48(5):505-515.
[46]Pisani T,Pantellini F,Centanni M,et al.Immunocytochemical expression of Ki67and laminin in Hurthle cell adcnomas and carcinomas[J].Anticancer Res,2003,23(4):3323-3326.
[47]林海利,郑周达,陈森期,等.ki67、p504s、p53联合检测在前列腺癌中的临床意义研究[J].中华泌尿杂志,2008,23(5):123-126.
[48]方志启,吴刚,陈晓宇等增殖和凋亡基因Ki—67、bcl—2、bax在前列腺增生、前列腺癌组织细胞中的表达及相关性[J].安徽医科大学学报,2007,42(4):391-394.
[49]阎洪涛,龚百生,廖勇,等.前列腺癌P53和PCNA表达的相关性研究[J].四川医学,2005,26(4):429-431.
[1]Folkman J.Tumor angiogenesis:rapeutic implications [J].N En-J,1971,285(20):1182-1186.
[2]Folkman J.Anti—angiogenesis:new concept for therapy of solid tumor3 [J].Anm Surg,1972,175(3):409-416.
[3]Kuiper RA,Schellens JH,Blijham GH,et al.Clinical research on antiangiogenic therapy [J].Pharmacol Res,1998,37(1):12-17.
[4]Maeda K,Chung YS,Takatsuka S,et al.Tumor angiogenesis as a predictor of recurrence in gastric carcinoma [J].J Clin Oncol,1995,13(2):477-481.
[5]Folkman J,Shing Y.Angiogenesis [M].J Bio Chem,1992,26(7):10931-37.
[6]Ohea H,Takagi H,Suzuma K,et al.Hypoxia and vascular endothelial growth factor selective up regulate angiopoietin-2 in bovine microvascular endothelial cells [J].J Biol hem,1999,274(2):15732-15746.
[7]Gunga HC,Kirsch K,Rocker L,et al.Vascular endothelial growth factor in exercising humans under different environmental conditions[J].Eur J Appl Physiol,1999,79(5):484-489.
[8]Norio H,Hisashi T,Mitsuo T,et al.Hepatocyte growth factorpromotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine [J].Oncogene,2002,21(7):1791-1977.
[9]Weidner N,Semple JP,Welch JR,et al.Tumor angiogenesis and metastasis-correlation in invasive breast cancer [J].N Engl JMed,1991,324 (5):111-114.
[10]Lewis JS,Landers RJ,Underwood JC,et al.Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas [J].J Pathol,2000,192(3):150-153.
[11]Wirigmann Vs,Plate KH,et al.genetics and cell biology of hemangioblastomis [J].Histol Histopathol,1996,11(4):1049-1061.
[12]Vahola RP,Salven P,Heikkila J,et al.VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer [J].Am.Patho,1999,154 (1):1381-1390.
[13]Witmer,AN,van Blijswijk BC,Hoffman,TA.et,al.VEGFR-3 in adult angiogenesis [J].Schlingemann Pathol,2001,195(7):490-497.
[14]Aguayo A,O'Brien S,Keating M,et al.Clinical relevance of intreelluar vascular endothelial growth factor levels in B-cell chronic lymphocyte leukemia [J].Blood,2000,96(2):769-770.
[15]Karkkainen MJ,Makinen T,Alitalo K.Lymphaticendothelium:a new frontier of metastasis research [J].Nat Cell Biol,2002,4(1):E2-5.
[16]Gasparini G,Toi M,Gion M,et al.Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma [J].J Natl Cancerlnst,1997,89(2):139-141.
[17]Frelin C,Ladoux A,Dangelo G.Vascular endothelial growth factors and angiogenis [J].Ann Endcefinol Paris,2000,61(1):70-74.
[18]Skobe M,Hawighorst T,Jackson DG,et al.Induction of tumorlym phanglogenesis by VEGF-C promotes breast cancer metastasis [J].Nat Med,2001,7(2):192-198.
[19]Joukov V,Pajusola K,Kaipainen A,et al.A novel vascular endothelial growth factor.VEGF-C is a ligand for the FLT4 (VEGFR-3) and KDR (VEGFR-2)receptor tyrosine kinases[J].EMBO J,1996,15(2):290-297.
[20]Jacquemier J,Mathoulin-Portier MP,Vahola R,et al.Prognosis of breast carcinoma lymphangiogenesis evaluated by immunohistochemicnal investigation of vascular endothelial growth factor receptor 3[J].Int J Cancer,2000,89(1): 69-73.
[21]Veikkola T,Jussila L,Makinen T,et aL.Signaling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice [J].EMBO J,2001,20(6):1223-1229.
[22]Jershenwald JE,Fidler U.et al.Targeting lymphatic metastasis [J].Science,2002,29(54):1811-1819.
[23]Mattila MT,Ruohola JK,Karpanen T,et al.VEGF C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors [J].Int J Caneer,2002,98:946-951.
[24]Jacquemier MJ,Mathoulin-Portier R,Vahola,E.et al.Prognosis of breast carcinoma lymphanogenesis evaluated by immunohistochemical investigation of vascular-endothelial-growth-factorreceptor [J].Bimbaum,2000,Int.Cancer89 (5):69-73.
[25]Salven P,Lymlbossaki A,Heikkila P,et al.Vascular endothelial growth factor VEGF-B and VEGF-C are expressed in human tumor [J].Am J pathol,1998,153(1):103-108.
[26]Vander Geer P,Hunter T,Lindberg RA.et al.Receptor protein-Tyrosine kinases and their signal transduction pathways [J].Annu Rev Cell Biol,1994,4(1):10251-10257.
[27]Mattern J,Koomagi R,Volm M.et al.Vascular endothelial growth factor expression and angiogenesis in no small cell lung carcinomas [J].International Journal of Oncology,1995,6(1):1059-1062.
[28]Delongchamps NB,Peyromaure M,et al.The role of vascular endothelial growth factor in kidney and prostate cancer [J].Can J Urol,2007,14(5):3669-3677.
[29]Liu F.Zhang YJ.et al.Roles of VEGF-C and its receptor Fit-4 in proliferation and metastasis of primary breast cancer[J].Ai Zheng.2003,22(10):1053-1056.
[30]Yang J,Wu HF,Qian LX,et al.Increased expressions of vascular endothelial growth factor (VEGF),VEGF-C and VEGF receptor-3 in prostate cancer tissue areassociated with tumor progression [J].Asian J Androl,2006,8(2):169-75.
[31]Kral J,Waltenberger J,et al.The vascular endothelia]growth factor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells[J].J Biol Chem,1997,272(51):32521-32527
[32]Dvorak H F,Broun LF,Detmar M,et al.vascular permeability factor/vascular endothelial growth factor,micro vascular hyper-permeability and angiogenesis[J].Am I pathol,1995,14(6):1029-1034
[33]Koseoglu RD,Erdemir F,Parlaktas BS,et al.Effect of chronic prostatitis on angiogenic activity and serum prostate specific antigen level in benign prostatic hyperplasia [J].Kaohsiung J Med Sci,2007,23(8):387-394.
[34]Sunny Y.Wong,Herbert Haack,et al.Tumor-Secreted Vascular Endothelial Growth Factor-C Is Necessary for Prostate Cancer Lymphangiogenesis,but Lymphangiogenesis Is Unnecessary for Lymph Node Metastasis [J].Cell and Tumor Biology,2007,65(2):110-116.
[35]Yi T,Yi Z,Cho SG,Luo J,et al.Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling[J].Cancer Res,2008,Mar 15,68(6):1843-1850.
[36]Peyromaure M,Badoual C,Camparo P,et al.Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer [J].Oncol Res.,2007,18(1):145-149.
[37]Peyromaure M,Camparo P,Badoual C,et al.The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostate-ctomy [J].BJU Int.,2007,99(5):1150-1153.
[38]Mao K,Camparo P,Badoual C,et al.The association of vascular endothelial growth factor receptor-1 with the risk of cancer progression following radical prostatectomy [J].Oncol Rep,2008,19(1):171-175.
[39]West AF,O'Donnell M,Charlton RG,et al.Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinic pathologic parameters in human prostate cancer [J].2001,85(4):576-583.
[40]Huber PE,Bischof M,Jenne J,et al.Trimodal cancer treatment:beneficial effects of combined anti angiogenesis,radiation,and chemotherapy [J].Cancer Res,2005,65(9):3643-3655.
[41]Jennbacken K,Vallbo C,Wang W,et al.Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis [J].Prostate,2005,65(2):110-116.